-

Catalent, Inc. to Present at June 2020 Virtual Investor Conferences

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will present at two upcoming virtual investor conferences.

On June 3, 2020 at 11:00 a.m. ET, the Company will present at the Jefferies 2020 Healthcare Conference. On June 10, 2020 at 9:00 a.m. ET, the Company will present at the William Blair 40th Annual Growth Stock Conference.

A live webcast of both presentations will be accessible through the Company’s website at http://investor.catalent.com and will be available for replay following the event.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs more than 13,500 people, including approximately 2,400 scientists, at more than 40 facilities across four continents and in fiscal 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, please visit www.catalent.com.

More products. Better treatments. Reliably supplied.™

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

Industry:

Catalent, Inc.

NYSE:CTLT
Release Versions
English

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

More News From Catalent, Inc.

Catalent Appoints Wetteny Joseph Group President, Pharma and Consumer Health

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, has appointed Wetteny Joseph as Group President, Pharma and Consumer Health (PCH), effective today. Joseph will lead Catalent’s PCH segment focusing on oral delivery technologies and manufacturing for small and macro molecules, and advanced delivery of self-care solutions, joining Catalent’s Group Executive Commi...

Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio

TAMPA, Fla. & WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, and Mantra™, a consumer health company developing single-serve, over the counter (OTC) oral gel products for everyday relief, today announced a commercial supply agreement for Mantra’s oral gel product platform. Catalent will provide formulation development, commercial manufacturing and pa...

Catalent Launches Accelerated Gene-to-Drug Substance Program for Complex Molecules in the U.S.

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the U.S. launch of an accelerated gene-to-drug substance program for complex biologics, designed to help developers move bispecifics, multispecifics and other next-generation molecules from gene sequence to drug substance in 10 months. The program builds on Catalent's Rapid Antibody offering for t...
Back to Newsroom